Update: Distribution of Veklury® (remdesivir)

Effective October 1, 2020, Veklury (remdesivir) will no longer be allocated by the U.S. Department of Health and Human Services (HHS), the Office of the Assistant Secretary for Preparedness and Response (ASPR) and State Departments of Health. This change is possible given that there is now sufficient supply of Veklury (remdesivir) to meet demand, even if a surge of COVID-19 cases occurs.

Starting October 1, 2020, hospitals can submit orders for Veklury (remdesivir) directly to AmerisourceBergen for the treatment of hospitalized COVID-19 patients. With this change, AmerisourceBergen, through its specialty distribution capabilities, will remain the sole U.S. distributor of Veklury (remdesivir) through the end of this year. It is important to note that orders should be placed on an as needed basis to treat current patients in accordance with EUA documentation for Veklury (remdesivir).

AmerisourceBergen will continue to source and sell two formulations of Veklury (remdesivir) from Gilead Sciences, including lyophilized powder, which is stored at ambient temperatures, and liquid vials, which are refrigerated.

Veklury (remdesivir) will be available in AmerisourceBergen ordering platforms for inpatient settings only, using the following item numbers:

- Veklury lyophilized powder: Item number 57889
- Veklury liquid solution: Item number 57890

**Ordering**
Orders of Veklury (remdesivir) can be placed by calling or emailing AmerisourceBergen Customer Service and through AmerisourceBergen ordering platforms.

**Pricing**
Pricing will not change, and customers can expect the same Wholesale Acquisition Cost (WAC), which is approximately $3,200 per treatment course.

- For additional information regarding purchasing or how to access Veklury (remdesivir), please email remdesivir@amerisourcebergen.com, or call 1-800-746-6273 or reach out directly to your AmerisourceBergen representative.
- For information on clinical trials that are testing the use of remdesivir in COVID-19, please visit www.clinicaltrials.gov.
- For additional medical information about Veklury (remdesivir), please visit https://www.askgileadmedical.com/remdesivir/ or call 1-866-MEDI-GSI (1-866-633-4474) Monday – Friday, 6am – 4pm PT.